Port Erin Share Discussion Threads

[adred] 11/12/2012 16:28

Share price 5.25 pence

Net asset value per share of 9.47 pence!


Synergy now $5.23 (up from $3.00 drop due to delay in filing)

Plecanatide Phase IIb/III result are expected in first week of Jan 13 less than a month away.

Exciting times ahead for Synergy and Port Erin.

Hopefully the share price should start moving northward as shareholders have seen the price drop from 10p to 5.25p.

As a shareholder it is disappointing and the warrents issued at IPO are worthless.

[kristini2] 11/11/2012 17:10

the large holding in synergy which made an after hours rns friday stating that filing has been delayed because of hurricane, big fall likely on this nasduaq stock on monday !

[kristini2] 06/11/2012 10:09

NAV was 9p last time around, looks a great long term buy

[ronan7] 06/11/2012 09:57

wow that was long

[pugugly] 06/11/2012 09:46

Falling out of bed today - Any thoughts ?

[mildred49] 16/6/2012 16:00

Some have speculated that TW mentioned PEBI in a recent article and the coincidental increased liquidity resulting would allow him to sell allied to the fact that as he was no longer a Director he was no longer required to inform the market of sales.

Funny hey ?

No one trusts TW it seems.

Check the RIVP thread for full exposure of his terrible track record

[orado] 16/6/2012 15:22

TW followers?

Surely he doesn't have any!

[kristini2] 16/6/2012 14:23

are these TW followers selling out causing the drop?

must be

[redali] 10/11/2011 12:31

Port Erin has invested in Arrowhead.

Wildly reported in the media today

Daily Mail "Pot belly blaster: A jab to banish 40% of body fat in just a month"


Arrowhead Research Subsidiary Ablaris Therapeutics Data Published in Science
Translational Medicine Demonstrates Weight Loss in Obese Monkeys






PASADENA, Calif. - November 10, 2011 - Arrowhead Research Corporation (NASDAQ: ARWR), a nanomedicine company with development programs in oncology, obesity, and regenerative medicine, today announced the publication of data from Ablaris Therapeutics, Inc.'s lead drug candidate, Adipotide™, demonstrating weight loss and reduction in body mass index and abdominal circumference in obese rhesus monkeys. The data, which was published in Science Translational Medicine (Sci Trans Med 3, 108ra112 (2011) DOI: 10.1126/scitraslmed.3002621), demonstrates that monkeys treated with Adipotide lost an average of 11 percent of their body weight after only four weeks of treatment. In addition, Adipotide-treated animals showed marked improvements in insulin resistance (using about 60 percent less insulin after treatment compared to baseline), suggesting potential for use in treating type-2 diabetes. The publication may be found at

The findings, presented in a paper titled, "A Peptidomimetic Targeting White Fat Causes Weight Loss and Improved Insulin Resistance in Obese Monkeys," and co-authored by Wadih Arap, M.D., Ph.D., and Renata Pasqualini, Ph.D., professors at the David H. Koch Center at the University of Texas MD Anderson Cancer Center in Houston ("MD Anderson"), reveal a promising pharmacological way to substantially reduce accumulated fat in non-human primates, and potentially humans. Unlike most anti-obesity drugs, which attempt to control appetite or prevent absorption of dietary fat, Adipotide directly attacks subcutaneous and visceral fat. The drug, a combination of a homing agent that binds to a protein on the surface of fat-supporting blood vessels, and a synthetic peptide that triggers cell death, removes the blood supply from fat cells, allowing them to be reabsorbed and metabolized. The study expands on previous work done in rodent models across two independent laboratories, which demonstrated similarly dramatic effects. The current study is thought to be highly clinically relevant because it was done with primates and the animals were "spontaneously" obese. That is, no human intervention was made to increase their weight; they became obese by over eating the same foods provided to other monkeys in the colony and avoiding physical activity.

"Safely and effectively treating the obesity epidemic is one of the great unmet needs in medicine today," said Dr. Christopher Anzalone, President and Chief Executive Officer of Arrowhead. "This study is a radical step forward for both Ablaris' technology and the treatment of obesity. It is uncommon for an obesity treatment to be successfully translated from rodent studies to non-human primates. Ablaris' approach is distinguished from others in the field by its unique mode of action. By acting directly on the vasculature that supports fat tissue rather than on the brain, we believe that we can avoid many of the safety issues that have blocked other anti-obesity drug candidates. We are extremely encouraged by the results achieved to date with Adipotide and believe that Ablaris' unique technology offers a significant advantage to combating obesity as we prepare to enter the clinic in the near-term."

[kibes] 14/10/2011 12:41

How can this be a biopharma investment company with only £3 million to play with? Its ludicrously small, that won't even cover the directors salaries let alone management costs.

[alwilliamson] 14/10/2011 11:25

RNS today that details the first 14 investments.

[baton] 19/9/2011 02:19

windass

Can you put an intraday chart in the header please.

[windass] 16/9/2011 18:34

seconduser

Of course City Equities sold their holding. That is what they do. Buy them at IPO then flog them on to their clients.

[outsizeclothes.com] 16/9/2011 15:48

Saw this fall today to roughly cash value, and decided to take a small punt on 50k @ 8.75p.
The main reason is that I heard his talk in Master Investor, which was pretty inspirational. But I'm not expecting anything much to happen, apart from initial purchases, for 3+ years.

[timtom2] 16/9/2011 15:23

Will stick with BIOG and WWH personally. The Bio area will move up massively but it's not an area you can look into for 2 years (JM) and then expect to get ahead. Lots of risk, some charlatans no doubt, and a lot of time needs investing - more than 2 years whilst JM was probably fighting fires elsewhere - Germany? Not everything he touches turns to gold. I seem to remember last year - BILL was supposed to be a big one for him. How about MFX? He can afford to play & take big risks.

Bio industry wil be the next big bubble - 2020 perhaps.

[seconduser] 16/9/2011 08:56

Got to agree with you uggly. Looks like City Equities dumped 1.5 million already.

[uggly buggly] 15/9/2011 17:53

My experience of AIM and pharmas is: ended in tears